. In contrast, other studies pointed to a positive role for cyclin C-CDK8 in mediating transcriptional activation, either as a part of basal transcriptional machinery, or downstream of p53, and of the Wnt/β-catenin pathway [22] [23] [24] [25] [26] . The human CCNC gene encoding cyclin C is located on chromosome 6q21, within the segment that is frequently deleted in several tumour types 27 . Indeed, heterozygous deletion of the CCNC gene was reported in human acute lymphoblastic leukaemia 27 and osteosarcomas 28 , and was postulated to play a role in tumorigenesis. However, other authors observed that the CCNC gene is amplified and overexpressed in human tumours [29] [30] [31] [32] [33] . To study the molecular role of cyclin C in a living organism, we generated conditional cyclin C-knockout mice. We then used these mice to unravel the molecular functions of cyclin C in vivo in normal development and in tumorigenesis.
RESULTS

Phenotype of cyclin C-null embryos
Conditional cyclin C-knockout (cyclin C F/F ) mice were generated using standard procedures (Fig. 1a-c) . We first converted the 'floxed' cyclin C allele into a cyclin C-null one (C ) and evaluated the consequence of germline cyclin C ablation for embryonic development. Cyclin C-null (C / ) mice died in utero at embryonic day 10.5 ( Fig. 1d ). Gross and histopathological analyses revealed a severe developmental retardation of mutant embryos, and an underdeveloped placental labyrinth layer (Fig. 1d ,e).
Molecular analyses of cyclin C-null cells
To analyse the function of cyclin C at the molecular level, we derived embryonic fibroblasts (MEFs) from conditional cyclin C-knockout mice and transduced them with Cre, thereby acutely deleting the cyclin C gene. We immunoprecipitated CDK8 and performed in vitro kinase assays using RNA polymerase II CTD as a substrate. The kinase activity of CDK8 was lost in cyclin C / cells (Fig. 2a) , consistent with the notion that CDK8 is activated by cyclin C. However, phosphorylation of the endogenous CTD remained unaffected by cyclin C shutdown (Fig. 2b) , revealing that other kinases are able to maintain normal CTD phosphorylation levels. Cyclin C together with CDK8 and MED12 and MED13 proteins forms an inhibitory mediator module, which sterically blocks interaction of the core mediator complex with RNA polymerase II (refs 16,17) . As expected, no interaction of cyclin C with MED12 and MED13 was observed in cyclin C-null cells (Fig. 2c, upper  panel) . Importantly, interaction of CDK8 with these proteins was also abolished following shutdown of cyclin C (Fig. 2c , middle and lower panels), revealing that cyclin C is required for CDK8 incorporation into the inhibitory mediator module.
We next evaluated the effect of cyclin C ablation on gene expression, by comparing gene expression profiles between control and cyclin C / MEFs, embryonic stem cells (ESCs) and brains (the last of these derived from E18.5 Nestin-Cre 34 /cyclin C F/F embryos), using microarrays. Shutdown of cyclin C had no major impact on global transcript levels (Fig. 2d,e) , suggesting that cyclin C is not essential for controlling global transcription under normal conditions in the analysed compartments.
To gauge the effect of cyclin C loss on cell proliferation, we compared growth rates between cyclin C F/F versus C / MEFs. An acute ablation of cyclin C had no impact on cell growth (Fig. 3a) . Moreover, cyclin C-null cells exhibited unperturbed fractions of cells in G 1 , S and G 2 /M phases (Fig. 3b) . However, cyclin C-null cells presented a defect in cell cycle re-entry from quiescence, especially when stimulated with lower concentrations of serum (Fig. 3c , left and middle panels). Importantly, genetic ablation of pRB fully restored the ability of cyclin C-null cells to re-enter the cell cycle (Fig. 3c , right panel, compare cyclin C / versus double-knockout C / /Rb / cells). These observations suggest that pRB represents the rate-limiting target of cyclin C in cell cycle re-entry. The function of cyclin C in cell cycle re-entry was proposed to be mediated by association with CDK3 (ref. 7) . However, laboratory mouse strains contain a nonsense mutation within the Cdk3 gene 35 . We observed that in mouse cells cyclin C interacts with the related kinases Cdk1 and Cdk2 (Fig. 3d-f ). Taken together, cyclin C is dispensable for continuous cell proliferation, but it plays a pRB-dependent role in cell cycle re-entry.
Upregulation of ICN1 following cyclin C ablation
To evaluate the impact of an acute cyclin C shutdown in a living mouse, we crossed cyclin C F/F mice with the Mx1-Cre strain and obtained cyclin C F/F /Mx1-Cre animals. The Mx1-Cre strain expresses inducible Cre-recombinase; administration of polyinosinic-polycytidylic acid (pI-pC) to Mx1-Cre animals activates Cre in haematopoietic cells, leading to deletion of the 'floxed' sequences 36 ( Supplementary Fig. 1a ). Unexpectedly, an acute ablation of cyclin C in vivo triggered enlargement of animals' thymuses (Fig. 4a) , and increased the number of thymocytes ( Fig. 4b and Supplementary Fig. 1b-d) .
Immunoblot analysis of cyclin C / thymocytes revealed strongly increased levels of ICN1 ( Fig. 4c and Supplementary Fig. 1e,f) . Importantly, the levels of Notch1 transcripts were unperturbed in cyclin Cnull thymocytes (Fig. 4d ), ruling out a transcriptional effect of cyclin C ablation on Notch1 levels. Moreover, the levels of full-length Notch1 10,000 (C-KO) MEFs, n = 3. P = 0.8 (day 4), P = 0.8 (day 5), P = 0.7 (day 6, all using t-tests). Error bars, s.d. (b) Fraction of Ctrl and C-KO MEFs in different cell cycle phases, visualized by propidium iodide (PI; DNA content) and anti-BrdU staining followed by FACS. (c) MEFs were rendered quiescent by serum starvation, and then stimulated to reenter the cell cycle from G 0 by addition of medium containing the indicated concentrations of serum (FCS). Entry of cells into the S-phase was evaluated by measuring [ 3 H]-thymidine uptake. Left panel: P = 0.003 (at 18 h); middle panel: P = 0.028 (at 18 h); right panel:
, both at 12 h. P values were determined by t-tests (n = 3 biological replicates). (d) Wild-type MEFs were arrested in G 0 as above, and then stimulated to re-enter the cell cycle by addition of medium containing 10% serum. Upper panel: at the indicated time points, cyclin C was immunoprecipitated and used for in vitro kinase reactions with recombinant pRB as a substrate in the presence of γ[
32 P]ATP. 32 P-pRB denotes phosphorylated pRB, detected by autoradiography. Lower panel: the levels of cyclin C at the indicated time points were determined by western blotting. (e) CDK1 or CDK2 was immunoprecipitated from quiescent MEFs (0 h), or at 6 h after serum stimulation, or from asynchronously growing cells (Cycling). Immunoblots were probed with the indicated antibodies. Lysate, denotes straight lysate from cycling cells. (f) Flag-tagged CDK2 was expressed in 293T cells and immunoprecipitated (IP) with an anti-Flag antibody. Complexes were eluted with a Flag peptide, re-immunoprecipitated (re-IP) with an anti-cyclin C antibody (or, for control with IgG), and used for in vitro kinase reactions with recombinant pRB as a substrate.
32 P-pRB denotes phosphorylated pRB, detected by autoradiography. Uncropped images of blots are shown in Supplementary Fig. 8 .
protein as well as membrane-bound Notch1 were unchanged in cyclin C / thymocytes (Fig. 4c and data not shown), indicating that cyclin C specifically controls the protein levels of ICN1. Ablation of cyclin C also led to strong upregulation of ICN1 in bone marrow cells (Fig. 4e) , which exhibited an enhanced propensity to differentiate along the T-cell lineage ( Supplementary  Fig. 1g-j) . Furthermore, when bone marrows of wild-type mice were reconstituted with a 1:1 mixture of wild-type (CD45.1 + ) and cyclin C / (CD45.2 + ) haematopoietic cells, cyclin C-null cells strongly outcompeted wild-type cells in their contribution to the T-cell lineage, consistent with Notch1 overactivation (Fig. 4f) .
A strong increase of ICN1 levels was not restricted to haematopoietic cells, as it was also observed in cyclin C / embryonic stem cells (Fig. 4g) and MEFs (Fig. 4h) . Importantly, re-expression of cyclin C in cyclin C / MEFs restored normal ICN1 levels ( Fig. 4i ).
Cyclin C controls ICN1 stability in vivo
To understand the molecular basis of the increased ICN1 levels in cyclin C / cells, we cultured control and C / thymocytes in the presence of cycloheximide (to block protein synthesis) or with a γ-secretase inhibitor (to inhibit production of ICN1), and monitored the decay of ICN1 levels over time. Cyclin C ablation resulted in a significantly prolonged half-life of ICN1 ( Supplementary Fig. 2a,b) . Moreover, treatment of thymocytes with proteosomal inhibitors partially reversed the differences in ICN1 levels between control and C / cells ( Supplementary Fig. 2c ), indicating that defective ICN1 degradation may underlie the increased ICN1 levels in cyclin C-null cells.
To extend these studies to human cells, we depleted cyclin C in T-ALL MOLT-16 cells using short hairpin RNAs (shRNAs).
This led to strong upregulation of ICN1, without affecting the levels of full-length Notch1 ( Fig. 4j and Supplementary Fig. 3a-d) . Knockdown of cyclin C strongly stabilized ICN1 and prolonged its half-life ( Supplementary Fig. 3c ). Conversely, overexpression of cyclin C resulted in suppression of ICN1 levels, again without having any obvious effect on full-length Notch1 ( Supplementary  Fig. 3e,f) . Collectively, these analyses indicated that cyclin C acts as a rate-limiting repressor of ICN1 levels by affecting the ICN1 protein-degradation rate. 
In vivo
In vitro Ankyrin repeat, transactivation domain (TAD) and PEST domains marked. Numbers above the ICN1 depict residues identified to be phosphorylated by cyclin-C-CDK8 in vitro; numbers below show residues that were detected in a phosphorylated form in vivo. (h) Protein extracts were prepared from thymocytes from cyclin C F/F /Mx1-Cre − (Ctrl) and C / /Mx1-Cre (C-KO) mice, ICN1 was immunoprecipitated (IP) and immunoblots were probed with a phospho-specific antibody against Ser-2517-phosphorylated ICN1 (phospho-ICN1), or with anti-ICN1 antibody. Input denotes whole-cell extracts. (i) Purified recombinant GST-ICN1 was pre-incubated in the presence (+) or absence (−) of cyclin-C-CDK8 kinase. Subsequently, GST-ICN1 was incubated with an in vitro translated 35 S-labelled Fbw7. ICN1-bound proteins were visualized by autoradiography. GST beads were used as a negative control. Input: an aliquot of radiolabelled Fbw7. Note that ICN1 interacted with Fbw7 only after pre-incubation with cyclin-C-CDK8. Lower panel: Coomassie-stained gel. The middle portion of the gel was cut out and the images were spliced together (dashed line). (j) Protein extracts were prepared from thymocytes from Ctrl and C-KO mice (as in h). Polyubiquitylated proteins were captured with Halo-TUBE (AP, affinity purification polyubiquitin), and immunoblotted with the indicated antibodies. Input, cell extracts. Note reduced polyubiquitylation of the endogenous ICN1 in C-KO thymocytes. Uncropped images of blots are shown in Supplementary Fig. 8 .
Cyclin C-CDK8, C-CDK19 and C-CDK3 kinases phosphorylate ICN1 Shutdown of cyclin C in thymocytes decreased the abundance of slower migrating ICN1 species ( Supplementary Fig. 2c , compare lanes 3 versus 4, and 5 versus 6), suggesting that cyclin C might regulate ICN1 post-translational modification. The enzymatic functions of cyclin C have been attributed to its kinase partners, CDK8 and CDK3 (refs 7,14) . Mammalian cells also express a CDK8-related 'orphan' kinase, CDK19 (ref. 37; Supplementary  Fig. 4a ), for which the activating partner is unknown. We found that in MOLT-16 cells cyclin C physically interacts with CDK19 ( Fig. 5a ) and activates its kinase activity ( Fig. 5e and Supplementary  Fig. 4f,g ). As expected, cyclin C also bound CDK8 and CDK3 in human cells (Fig. 5a ). Knockdown of CDK8, CDK19 or CDK3 in human cells, and knockdown of CDK8 or CDK19 in mouse cells, recapitulated the phenotype of cyclin C ablation, namely it upregulated ICN1 levels, without having any effect on fulllength Notch1 (Fig. 5b,c and Supplementary Fig. 4b-e) . Conversely, overexpression of CDK8, CDK19 or CDK3 strongly suppressed ICN1 levels without affecting full-length Notch1 ( Supplementary  Fig. 3e ,f). These observations suggested that cyclin C controls ICN1 levels through its kinase partners CDK8, CDK19 and CDK3. Using purified, recombinant proteins, and proteins immunoprecipitated from cells, we found that cyclin C-CDK8, C-CDK19 and C-CDK3 complexes can phosphorylate ICN1 (Fig. 5d-f and Supplementary Fig. 4f-i) .
Mapping of cyclin C-dependent phosphosites on ICN1, using mass spectrometry, revealed that several of them are located within the PEST-domain of Notch1, which controls ICN1 degradation 38, 39 ( Fig. 5g and Supplementary Table 1 ). Three of them (Thr 2512, Ser 2514 and Ser 2517) are localized within the consensus motif, 'Cdc4 phosphodegron' , which is shared by most substrates of Fbw7 (Cdc4) ubiquitin ligase 38 . Two of these residues (Ser 2514 and Ser 2517) were previously shown to be phosphorylated by cyclin C-CDK8 (ref. 20) , and all three were shown to play a role in controlling ICN1 stability through Fbw7 (ref. 40) . We verified that cyclin C-CDK8, C-CDK19 and C-CDK3 phosphorylate ICN1 on these three residues (Supplementary Fig. 5 and Supplementary Tables 1 and 2) .
We raised a phospho-specific antibody, which recognizes the Ser-2517-phosphorylated version of ICN1 ( Supplementary Fig. 6a,b ). Using this antibody we found that acute ablation of cyclin C diminished phosphorylation of the endogenous ICN1 on this residue in cyclin C / thymocytes (Fig. 5h ). Also knockdown of cyclin C in human T-ALL cells decreased Ser 2517 phosphorylation of the endogenous ICN1 ( Supplementary Fig. 6c ). Hence, cyclin Cassociated kinases control ICN1 phosphorylation in vivo.
Cyclin C-associated kinases regulate ICN1 polyubiquitylation in vivo
Using recombinant proteins, we established that binding of ICN1 to Fbw7 is critically dependent on pre-phosphorylation of ICN1 by cyclin C-CDK kinase (Fig. 5i) . Consistent with this, knockdown of cyclin C in human T-ALL cells, or ablation of cyclin C in MEFs, decreased interaction of ICN1 and Fbw7 proteins in vivo ( Supplementary Fig. 6c-f) .
Interaction of ICN1 with Fbw7 leads to ICN1 polyubiquitylation. Indeed, ablation of cyclin C strongly decreased polyubiquitylation of the endogenous ICN1 in cyclin C-null thymocytes (Fig. 5j) . Likewise, ubiquitylation of ICN1 was reduced in human cells following knockdown of cyclin C (Supplementary Fig. 6g ).
Collectively, these findings support a model in which cyclin C-CDK8/19/3 kinases phosphorylate ICN1 in vivo and allow binding of ICN1 to Fbw7, which then triggers ICN1 polyubiquitylation and proteolytic degradation. Ablation of cyclin C disrupts this process, leading to upregulated ICN1 levels in cyclin C-null mice.
Increased susceptibility of cyclin C-deficient animals to T-ALL
Despite elevated ICN1 levels in bone marrow (Fig. 4e) , cyclin C / /Mx1-Cre mice did not spontaneously develop tumours.
Previous work showed that elevations of ICN1 are not leukaemogenic on their own, but promote development of T-ALL when combined with other oncogenic lesions 41 . We therefore tested whether cyclin C loss would enhance T-ALL development by crossing cyclin C F/F /Mx1-Cre animals with Lck-LMO1 transgenic mice. The LMO1 gene represents a recurring target of chromosomal translocations in human T-ALL (ref. 42 ). Lck-LMO1 mice occasionally develop T-ALL after a long latency 43, 44 . Importantly, activation of Notch1 represents an obligatory step in oncogenesis in this model 45, 46 . We ablated cyclin C in cyclin C F/F /LMO1/Mx1-Cre animals (by pI-pC administration), and monitored them for tumour occurrence. Ablation of cyclin C strongly increased tumour incidence (Fig. 6a) , and elevated ICN1 levels in cyclin C / tumours (Fig. 6b) . These findings suggest that cyclin C may act as a tumour suppressor in T-ALL by controlling ICN1 protein levels. Transduction of murine haematopoietic progenitor cells (HPCs) with viruses encoding very high levels of activated Notch1 is sufficient to trigger T-ALL without additional lesions 41 ( Fig. 6c) . We collected HPCs from control and cyclin C / animals, and transduced them with oncogenic Notch1 alleles. The levels of ectopically expressed oncogenic Notch1 were strongly elevated in C / HPCs, as compared with Notch1-transduced control HPCs (Fig. 6d-f and Supplementary Fig. 7a,b) . We then injected HPCs into the bloodstream of sublethally irradiated C57BL/6 wild-type recipients and observed them for T-ALL occurrence (Fig. 6c) . The onset of leukaemia was significantly accelerated in recipients of cyclin C / HPCs ( Fig. 6h and Supplementary Fig. 7c-e) . Collectively, these observations indicate that the loss of cyclin C is not sufficient to trigger leukaemia on its own, but it accelerates T-ALL development when combined with other genetic lesions. We wished to confirm that the growth-suppressive role of cyclin C in T-ALL development is mediated through the ability of cyclin C-associated kinases to phosphorylate ICN1. We transduced control and C / HPCs with an ICN1 mutant in which the domain containing the three critical cyclin C-dependent residues (Thr 2512, Ser 2514, Ser 2517) had been deleted, and injected HPCs into recipient C57BL/6 mice. Strikingly, once the domain containing cyclin C-dependent phosphoresidues had been removed, ablation of cyclin C no longer accelerated T-ALL development ( Supplementary Fig. 7f ). Hence, the tumour-suppressive role of cyclin C in vivo is mediated through the ability of cyclin C to phosphorylate Notch1.
Cyclin C heterozygosity accelerates T-ALL
The human cyclin C gene (CCNC) is located on 6q21 within a region that is frequently deleted in breast, ovarian, prostate and lung cancers, osteosarcomas and in haematopoietic malignancies, including T-ALL (refs [47] [48] [49] [50] . Heterozygous deletion of CCNC was demonstrated in leukaemias and osteosarcomas, and proposed to contribute to tumorigenesis 27, 28 . Given the rate-limiting role of cyclin C in controlling ICN1 levels in vivo, demonstrated in this study, we analysed primary T-ALL patient samples and human T-ALL cell lines using array-comparative genomic hybridization (CGH). Chromosomal deletions involving CCNC were found in 13/150 primary patient samples and in 4/20 T-ALL cell lines (Fig. 7a,b) . Sequencing of the remaining cyclin C allele revealed no mutations in the coding sequence. However, the levels of cyclin C transcripts were reduced approximately twofold in T-ALL cases that sustained CCNC heterozygous deletion (Fig. 7c ). These observations hinted that cyclin C haploinsufficiency might contribute to T-ALL development. Supplementary Fig. 8 .
Intriguingly, the human CDK19 gene is also located on 6q21 in close proximity to CCNC (within 10 megabases), and it is hence often codeleted with CCNC (see also Supplementary Fig. 7g ).
To test whether heterozygosity at the cyclin C locus might contribute to tumorigenesis in vivo, we collected HPCs from heterozygous cyclin C +/ /Mx1-Cre animals. These cells expressed Shown is a dChip plot of the segmented CGH log 2 (copy number ratios) of the entire chromosome 6. The location of the CCNC locus is denoted by a red line. (c) Cyclin C expression was analysed using gene expression microarrays; analysis was performed on the subset of primary T-ALL patient samples depicted in a. Shown are cyclin C expression levels in tumours that exhibited heterozygous CCNC gene deletions (n = 6) versus tumours without CCNC deletion (CCNC no del, n = 34). P = 0.006 (Mann-Whitney test). Horizontal lines, mean; error bars, standard error of mean.
reduced levels of cyclin C, and elevated levels of endogenous ICN1 (Fig. 6d and Supplementary Fig. 7a,b) . We then transduced cyclin C +/ HPCs with oncogenic Notch1. As was the case in cyclin C-null HPCs, the levels of oncogenic ICN1 were elevated in C +/ HPCs, as compared with Notch1-transduced control cells (Fig. 6g) . We injected HPCs into recipient mice and observed them for tumour development. Strikingly, cyclin C heterozygosity accelerated T-ALL development to almost the same extent as a complete cyclin C ablation (Fig. 6i) . These results indicate that cyclin C represents a haploinsufficient tumour suppressor, and that the loss of one cyclin C allele is sufficient to accelerate leukaemia in vivo.
ICN1 mutations accelerate T-ALL by blocking cyclin C-dependent phosphorylation
We wished to determine whether in addition to CCNC deletions, the ability of cyclin C-CDK to phosphorylate ICN1 could be compromised in human T-ALL through other mechanisms.
As CDKs are proline-directed kinases 37 , we analysed our DNA sequencing data for the NOTCH1 gene from 73 T-ALL patients 51 and searched for mutations in prolines adjacent to the critical cyclin C-CDK-dependent phosphoresidues of ICN1 identified above. We observed four cases with substitutions involving proline residues: P2513A, P2513S, P2513L and P2515R, and one additional case with Ser 2514 mutated to phenylalanine (Fig. 8a) . We determined that each of these mutations compromised the ability of cyclin C-CDK8 to phosphorylate ICN1 on all three or on two out of three critical residues (Fig. 8b,c , and Supplementary Table 3 ). As expected from decreased phosphorylation, all five patient-derived Notch1 mutants showed greatly reduced interaction with Fbw7 (Fig. 8d,e) .
To evaluate the impact of these patient-derived mutations on tumorigenesis in vivo, we engineered an oncogenic Notch1-P12 allele 41 to express an S2514F mutation, or a combination of three patient-derived mutations (P2513A, S2514F and P2515R). We then transduced wild-type HPCs with viruses encoding these Notch1 T2512  S2514  S2517  T2512  S2514  S2517  T2512  S2514  S2517  T2512  S2514  S2517  T2512  S2514  S2517  0   50 . Note that all patient-derived mutants were compromised in their ability to bind Fbw7. Input, whole-cell lysates. (f) Mice received wild-type HPCs transduced with Notch1-P12 (n = 7), Notch1-P12 carrying a patient-derived S2514F mutation (n = 9) or Notch1-P12 with P2513A, S2514F and P2515R mutations (n = 6). Shown is a Kaplan-Meier analysis of survival. P = 0.03 for Notch1-P12 WT versus Notch1-P12 S2514F; P = 0.01 for Notch1-P12 WT versus Notch1-P12 P2513A/S2514F/P2515R (log-rank test). Uncropped images of blots are shown in Supplementary Fig. 8 .
alleles, and injected HPCs into C57BL/6 recipients. The disease was accelerated in recipients of S2514F Notch1-transduced cells, whereas the compound mutant markedly accelerated the disease (Fig. 8f) . Collectively, these results indicate that mutations that cripple the ability of cyclin C-CDK kinase to phosphorylate ICN1 contribute to T-ALL development in vivo.
DISCUSSION
Cyclin C was cloned as a protein that promotes cell cycle progression through the G 1 phase 1, 2 . Subsequent studies revealed that cyclin C represents a component of global transcriptional machinery, and that it represses gene expression [9] [10] [11] [12] [13] [14] [15] . Surprisingly, we found that the major, rate-limiting function of cyclin C in vivo in the haematopoietic lineage is to suppress ICN1 levels. We demonstrated that cyclin C-CDK8, C-CDK19 and C-CDK3 complexes serve as in vivo repressors of Notch1 by directly phosphorylating ICN1. Ablation of cyclin C, or cyclin C heterozygosity, leads to de-repression of ICN1 levels and accelerates T-ALL development. Thus, cyclin C acts to restrain proliferation of the T-cell lineage and functions as a growth suppressor. Furthermore, we describe point mutations in human tumours that render cyclin C-CDK unable to phosphorylate ICN1. These observations indicate that human T-ALL cells employ different strategies to disable cyclin C function.
Activation of Notch1 represents a driving force not only in T-ALL, but also in many other cancer types 52 . Deletions of 6q21 where the CCNC gene resides are seen in several human malignancies, including breast, prostate and lung cancers, as well as several types of leukaemia and lymphoma 27, 28, [47] [48] [49] [50] 53, 54 . It remains to be seen whether cyclin C plays a tumour-suppressive role in other cancer types, and whether this function is mediated by Notch1. Crossing of cyclin C F/F mice with strains expressing Cre in different compartments, along with analyses of human tumours, will help to address this point. It should be noted, however, that Notch1 can also function as a tumour suppressor, depending on the cellular context 55 . For example, Notch1 represents a well-established tumour suppressor in human squamous cell carcinoma [56] [57] [58] . It remains to be seen whether cyclin C can regulate ICN1 levels also in this context and, if so, whether it functions as an oncogene in some tumour types.
In addition to controlling Notch1 levels, cyclin C plays a pRBdependent role in facilitating G 0 exit [6] [7] [8] . Indeed, we observed a modestly impaired ability of cyclin C-null cells to re-enter the cell cycle. This function of cyclin C might promote tumorigenesis in certain compartments, in particular under circumstances where quiescent tumour-initiating cells enter the G 1 phase. Cyclin C may also affect cancer cells through other mechanisms. Indeed, in contrast to a growth-suppressive role for cyclin C-CDK8 in the T-cell lineage, demonstrated in this study, CDK8 was shown to function as an oncogene in human colon cancers, where it promotes β-catenindriven transcriptional activity and stimulates cell proliferation 23, 24 . Hence, CDK8 kinase represents an attractive target for therapeutic intervention in colon cancers. However, our study cautions that using CDK8 inhibitors for colon cancer treatment may elicit protumorigenic effects in other compartments.
METHODS
Methods and any associated references are available in the online version of the paper. 
Generation of conditional cyclin C-knockout mice. The conditional cyclin C gene-targeting construct was assembled by inserting loxP sites into the PvuII site in intron 1 and into the KpnI site in intron 7 of the murine Ccnc gene. In addition, a neomycin resistance (Neo) cassette, flanked by two FRT sites, was inserted into the PvuII site in intron 1. The 5 homology arm comprised a 2.2-kilobase (kb) SalI-PvuII fragment, and the 3 arm a 4-kb KpnI-BmgBI fragment of the Ccnc gene. The targeting construct was electroporated into ESCs, and cells that underwent homologous recombination were identified using Southern blotting with external probes (probes A and B in Fig. 1 ) and an EcoRI digest of genomic ESC DNA. Heterozygous animals were obtained using standard procedures. Animals were then bred with ACTFLPe mice (from the Jackson Laboratory) leading to deletion of the Neo cassette and to generation of cyclin C +/F mice. Cyclin C +/F mice were then interbred, giving rise to conditional knockout cyclin C F/F mice. For genotyping animals, the following PCR primers were used: P1: 5 -GGGG TGATGGTGAAAACACTGA-3 , P2: 5 -CAAGCAAGTAATCCAGGACCA-3 and P3: 5 -CTGCACATACTGGAGCAAAGGTCT-3 (Fig. 1a,c) . PCR was performed with a denaturation step at 95 • C for 3 min, followed by 30 cycles of 95 • C for 1 min, 60 • C for 1 min, 72 • C for 1 min, and a final elongation step at 72 • C for 5 min. The wild-type cyclin C + allele yields a 460-base-pair (bp) band, the cyclin C F allele a 520 bp band, and the cyclin C allele a 650 bp band (Fig. 1c) .
Mouse crosses and analyses. All mouse experiments were approved by the Dana-Farber Cancer Institute Animal Care and Users Committee. Cyclin C F/F mice were crossed with Mx1-Cre mice 36 (from the Jackson Laboratory). Four-to six-week-old cyclin C F/F /Mx1-Cre − (control), cyclin C +/F /Mx1-Cre and cyclin C F/F /Mx1-Cre mice were intraperitoneally injected five times with polyinosinic-polycytidylic acid (pI-pC, Amersham), 2.5 µg g −1 body weight on alternate days. Organs (thymuses, bone marrow) were collected 5-10 days after the last pI-pC dose and analysed by flow cytometry, or used to prepare protein lysates, for in vitro treatment of thymocytes. Thymocytes were stained with anti-CD4, anti-CD8, anti-CD25 (all from BD Pharmingen) and anti-CD44 (Biolegend) antibodies, and analysed by FACS.
Cyclin C F/F and Mx1-Cre mice were also crossed with the LMO1 transgenic strain 44 yielding cyclin C F/F /LMO1+/Mx1-Cre − (control) and cyclin C F/F /LMO1+/Mx1-Cre mice. Animals were injected with pI-pC, as above, at about 4-6 weeks of age, and were monitored for leukaemia occurrence by analysis of peripheral blood.
For isolation of MEFs, cyclin C F/F mice were crossed with Rb F/F mice (from the Jackson Laboratory). To delete cyclin C in the brain, cyclin C F/F mice were crossed with Nestin-Cre animals 34 . Brains were then collected from E18.5 cyclin C F/F /Nestin-Cre mice. The sample size was chosen on the basis of our experience in analysing phenotypes and tumour susceptibility of mice (no statistical method). All differences were tested for statistical significance (see 'Statistical analyses' below). No animals were excluded from the analysis. No randomization was used to determine how animals were allocated to experimental groups. The investigators were not blinded to group allocation. Mice were of the 129Sv/C57BL/6 background. For all experiments mice of both sexes, 6-12 weeks old were used, unless indicated otherwise in the figure legend.
Generation of mixed bone marrow chimaeras. Bone marrow cells from CD45.1 wild-type and CD45.2 cyclin C / /Mx1-Cre mice (approximately 2 weeks after the last pI-pC dose), or from CD45.2 wild-type mice, were stained with CD4, CD8α, TCRβ, TCRγδ and NK1.1 biotinylated antibodies followed by incubation with streptavidin-conjugated magnetic beads (Invitrogen) and magnetic bead depletion of T and NK cells. CD45.1 C57BL/6 recipients were subjected to lethal irradiation (1,000 rad) using a γ-cell 40 irradiator with a caesium source. Mixed (1:1) T-celland NK-cell-depleted bone marrow cells (4-8 × 10 6 ) were intra-orbitally injected into the recipient mice. Chimaeras were analysed at 11 weeks after the bone marrow transfer.
Retrovirus production and bone marrow transplantation. Murine Notch1-expressing ICN1-EGFP and pMigR1-Notch1-P12 retroviral constructs were described previously 59, 60 . Notch1-P12 mutants S2514F and P2513A/S2514F/P2515R were generated with the QuikChange II XL Site-Directed Mutagenesis kit (Stratagene). Retroviruses were produced by transient co-transfection of 293T or PlatE cells with Notch1-expressing constructs and appropriate packaging vectors as described previously. The titration of retroviruses was performed in NIH3T3 cells. Donor cyclin C F/F /Mx1-Cre − , cyclin C +/F /Mx1-Cre and cyclin C F/F /Mx1-Cre mice were injected 3-5 times with pI-pC. Bone marrow was collected 5-10 days after the last pI-pC dose. Retroviral transduction and bone marrow transplantation were carried out as follows: lineage-negative (CD3ε, TCR-β, NK1.1, DX5, CD19, Ter-119, Mac-1 and Gr-1) bone marrow cells were sorted and cultured with Flt3L, SCF (both 50 ng ml −1 ), IL-6, IL-7 and IL-3 (10 ng ml −1 ) (all from R&D Systems). On day 2 and day 4 after cell sorting, cells were subjected to retroviral transduction by spin infection with centrifugation at 1,300g for 1.5 h at room temperature with 8 µg ml −1 Polybrene. On day 5, 1-2 × 10 6 cells were injected intravenously into sub-lethally irradiated C57BL/6 recipient mice. Alternatively, cells were spin infected at 700g for 1.5 h at 30 • C on days 1 and 2, and 50,000 GFP + cells were retro-orbitally injected into irradiated recipients on day 3. In the experiment shown in Supplementary Fig. 7f , a EGF LNR Notch1 construct lacking amino acids 23-1562 and 2473-2556 (ref 61) was used for bone marrow transduction. Animals were monitored for leukaemia occurrence by analysis of peripheral blood. Peripheral blood GFP + cells were stained with anti-CD4 and anti-CD8 antibodies as above, and analysed by FACS.
For analyses of ICN1 levels ( Fig. 6e-g ), pI-pC-treated mice received one dose of 5-FU (150 mg kg −1 ) 4 days after the last pI-pC dose. Bone marrow cells were collected 6 days later and transduced with a retrovirus expressing Notch1-P12 and GFP. GFP + cells were sorted, and used for immunoblotting.
In vitro culture and analyses of bone marrow cells. To analyse bone marrow or thymocyte subpopulations, single-cell suspensions were prepared from bone marrow collected from femur and tibia or were isolated from the whole thymus. Cells were blocked with rat IgG (Sigma), stained with fluorescently conjugated antibodies in PBS/2% FCS on ice for 30 min, and analysed using a BD Fortessa. FACS plots were generated and quantified using FlowJo software (Treestar).
Bone marrow cells were stained for lineage markers: B220 (RA3-6B2), Gr1 (RB6-8C5), CD11b (M1/70), Ter119, CD4 (GK1.5) and CD8 (53-6.7), as well as c-kit (2B8), Sca1 (D7), CD34 (RAM34) and Flt3 (A2F10). Sub-populations were defined as follows: LT-HSC: Lin − , c-kit + , Sca1 + , CD34 − , Flt3 − ; ST-HSC: Lin − , c-kit + , Sca1 + , CD34 + , Flt3 − ; LMPP: Lin − , c-kit + , Sca1 + , CD34 + , Flt3 + ; CLP: Lin − , ckit lo , Sca1 lo , Flt3 + , IL7Rα + . To determine thymocyte subpopulations, thymocytes were stained for CD4 (GK1.5), CD8 (53-6.7), CD25 (PC61) and CD44 (IM7). Double-negative (CD4 − CD8 − ) thymocyte populations were sub-classified as follows: DN1: CD25 − , CD44 hi ; DN2: CD25 + , CD44 + ; DN3: CD25 + , CD44 − ; DN3-4: CD25 int , CD44 − ; DN4: CD25 − , CD44 − . All antibodies were purchased from eBioscience, BD Biosciences or BioLegend.
To perform in vitro analyses, Lin − bone marrow cells were cultured in Opti-MEM supplemented with 10% FCS, Flt3L (5 ng ml −1 ) and IL-7 (1 ng ml −1 ) either alone or co-cultured on a layer of OP9 stromal cells overexpressing delta-like 1 (DLL1) protein (OP9-DL1). In Fig. 6d and Supplementary Fig. 7a , cells were cultured for 48 h on OP9-DL1 stroma. To quantify proliferation, bromodeoxyuridine (BrdU, 10 µM) was added to the cultures for 1 h; cells were stained using the BrdU Flow Kit (BD Biosciences) and analysed by flow cytometry.
Immunostaining. Standard 4 µm formalin-fixed, paraffin-embedded tissue sections were stained using the Ventana Benchmark XT platform (Ventana Medical Systems) with extended heat-induced epitope retrieval (CC1 Buffer). Slides were incubated for 1 h at room temperature with anti-NICD1 rabbit monoclonal antibody (clone D3B8, catalogue number 4147, Cell Signaling, final concentration, 8.5 µg ml −1 ). Signals were then amplified (Ventana Amplification Kit) and visualized (Ventana Ultraview Universal DAB detection kit).
Western blotting and immunoprecipitation. Whole-cell extracts were obtained and proteins were solubilized for immunoblotting. The following antibodies were used: cyclin C (A301-989A, Bethyl, 1:500 or 1:1,000), CDK8 (C-19, Santa Cruz, 1:200-1:1,000), CDK19 (HPA007053, Sigma, 1:1,000 or 1:2,000) CDK3 (SC-826, Santa Cruz, 1:200), CDK1 (Ab-1, Thermo Scientific, 1:200), CDK2 (M2, Santa Cruz, 1:500), Notch ICN1 (V1744, Abcam, 1:500 or 1:1,000), Notch1 ICN1 (2421, Cell Signaling, 1:500 or 1:1,000), Notch1 full-length and membrane-bound (C-20, Santa Cruz, 1:500 or 1:1,000), c-Myc (9E10, Santa Cruz and ABC, Cell Signaling 1:500 or 1:1,000), FBW7 (A301-720A, Bethyl, 1:2,000), HA (A190-108A-4, Bethyl, 1:500), cyclin E1 (M-20, Santa Cruz, 1:500 or 1:2,000), Hisprobe (H-20, Santa Cruz, 1:300), GST (2622S, Cell Signaling, 1:1,000), GAPDH (D16H11, Cell Signaling 1:1,000), tubulin (DM1A, Sigma, 1:2,000 or 1:5,000), actin (AC40, Sigma, 1:3,000), β-actin (AC-15, Thermo Scientific, 1:5,000; or 4967, Cell Signaling, 1:1,000), CDK6 (C-21, Santa Cruz, 1:500), MCL1 (S19, Santa Cruz, 1:500 or 1:1,000), mTOR (2972, Cell Signaling, 1:1,000), c-Jun (9162, Cell signaling 1:500), pRB-pS807/811 (D20B12, Cell Signaling, 1:1,000), MED12 (A300-774A-1, Bethyl, 1:500), MED13 (A301-278A-1, Bethyl, 1:500), phospho-Rpb1 CTD (Ser 2/5) (4735S, Cell Signaling, 1:500), RNA polymerase II (05-623B, clone CTD4H8, Upstate 1:500), Flag (M2, Sigma, 1:1,000 or 1:4,000), ubiquitin (Z0458, Dako, 1:2,000). Crosslinked anti-c-Myc antibody (9B11, Cell Signaling 8 µl slurry) was used for immunoprecipitation.
For immunoprecipitation of endogenous ICN1 from MOLT-16 cells, 2 mg of MOLT-16 cell extracts was incubated with 2 µg Notch ICN1 antibody (ab52301, Abcam) for 12 h at 4 • C followed by 1 h incubation with protein A Sepharose beads (GE Healthcare). For immunoprecipitation of endogenous ICN1 from thymocytes, thymocytes were collected from cyclin C F/F /Mx1-Cre − and cyclin C / /Mx1-Cre mice, and cultured in the presence of MG132 (10 µM) for 6 h. Protein extracts were prepared, and extracts containing 2 mg of proteins were immunoprecipitated with anti-cleaved Notch1 (Val 1744) antibody (4147; Cell Signaling, 1:200) overnight at 4 • C, followed by 3 h incubation with protein A agarose beads (Cell Signaling). Blots with an anti-phospho-ICN1 (1:1,000) and total ICN1 (2421, Cell Signaling 1:500) antibodies, shown in Fig. 5h , are from separate immunoprecipitations. Immunocomplexes were resolved on SDS-PAGE gels. Immunoreactive proteins were detected using enhanced chemiluminescence reagents (GE Healthcare).
Generation of anti-phospho ICN1 antibody. Anti-phospho-Notch1 antibody was generated by Cell Signaling Technologies, by immunizing rabbits with peptides that were phosphorylated on both Ser 2514 and Ser 2517. Affinity-purified antibody was tested by immunoblotting protein lysates with anti-phospho-ICN1 antibody (1:1,000), or by immunoprecipitating ICN1-immunoblotting with anti-phospho-ICN1 antibody using lysates of cells engineered by us to express wild-type ICN1, ICN1-T2512A, ICN1-S2514A, ICN1-S2517A, ICN1-S2514A/2517A and ICN1-T2512A/S2514A/S2517A mutants. Mutation of Ser 2517 to alanine completely abolished immunoreactivity with anti-phospho-ICN1 antibody. On the other hand, mutating Ser 2514 (or Thr 2512) had no impact on the ability of the anti-phospho-ICN1 antibody to detect ICN1 ( Supplementary Fig. 6a,b) . Moreover, treatment of ICN1 immunoprecipitates with lambda phosphatase abolished the immunoreactivity ( Supplementary  Fig. 6b, lower panel) . We concluded that anti-phospho-ICN1 antibody recognizes ICN1 phosphorylated on Ser 2517. The antibody was used at 1:1,000 dilution.
Plasmids. HA-FBW7, FBW7 shRNA lentiviral vectors were described previously 62 . pcDNA3-CDK8-HA and pBabe-puro-CDK8 were purchased from Addgene. pMigRI-E LNotch1 retroviral vector and pcDNA3-ICN1 were described previously 61 . All Notch1 ICN1 mutants were generated with the QuikChange XL Site-Directed Mutagenesis kit (Stratagene). Lentiviral shRNA control constructs against GFP (CTR) and against human cyclin C (CycC1 shRNA: NM_005190.2-282s1c1, CycC2 shRNA: NM_005190.2-114s1c1, CycC3 shRNA: NM_16746.1-735s1c1) were obtained from W. Hahn (Dana-Farber Cancer Institute), against human CDK8, CDK3 and CDK19 were purchased from Open Biosystems, control construct against GFP (CTR in Fig. 5b,c) was obtained from F. Schmit (Dana-Farber Cancer Institute), against mouse Cdk8 (Cdk8-shRNA1: NM_153599.2-1104s1c1, Cdk8-shRNA2: NM_153599.3-1893s21c1) and Cdk19 (Cdk19-shRNA1: NM_198164.1-955s1c1, Cdk19-shRNA2: NM_198164.2-624s21c1, Cdk19-shRNA3: NM_198164.1-1491s1c1) were obtained from the TRC shRNA library. pMigICN1 retrovirus vector was generated by subcloning human ICN1 cDNA into the pMigII vector. GST-ICN1 was generated by subcloning human ICN1 cDNA into pGEX5.1 vector. Lentiviral CDK expression plasmids were constructed by subcloning human CDK8, CDK3 or CDK19 cDNA into the pLenti-GFP-puro vector. pFN18A-Halo-TUBE plasmid was obtained from P. Cohen (MRCPPU, Dundee, UK).
Cell culture. Thymocytes were cultured in RPMI 1640 with 10% FCS. Cells were treated with proteasome inhibitor MG132 (10 µM; Calbiochem) and lactacystin (10 µM; Enzo), or with vehicle alone (DMSO) six hours before protein extraction. For ICN1 half-life studies, cycloheximide (20 µg ml −1 , Sigma) or γ-secretase inhibitor Compound E (200 nmol, Enzo) was added to the media, and cells were collected at the indicated time points.
Cyclin C F/F MEFs were prepared from E13.5 embryos. For experiments with Notch1-expression, cells were immortalized with a dominant-negative p53 construct. Cells were treated with AdenoCre (MOI 100, Harvard Gene Therapy Initiative) to delete cyclin C and to generate cyclin C Fig. 6d ) or pMig-E LNotch1GFP expressing human Notch1 without the EGF-like repeats 1-36 and the three Lin12/Notch repeats (residues 23-1562) (Figs 4h,i and 5b,c, and Supplementary Fig. 6f ). Subsequently, cells were treated with adenoviruses expressing Cre (MOI 100), or empty vector. In Fig. 4i , cyclin C F/F MEFs were engineered to stably express cyclin C, using pOZ-FH-N expression vector, and then were transduced with pMig-E LNotch1GFP retrovirus. Cells were then treated with adenoviruses expressing Cre (C / ), or empty vector (C F/F ). In the experiment shown in Supplementary Fig. 6f , a mutant version of Notch1 (TSS: T2512A/S2514A/S2517A) was used. In Supplementary Fig. 6d , cells were treated with 10 µM MG132 for 6-10 h before protein extraction. In the experiments shown in Fig. 5b ,c, cyclin C F/F MEFs were infected with pMigRI-E LNotch1GFP retroviral vector. Subsequently, cells were transduced with lentiviruses encoding shRNAs targeting murine Cdk8 or Cdk19 and selected with puromycin. Cells were collected 72 h after lentiviral infection.
HeLa cells (ATCC) were maintained in DMEM (Invitrogen) supplemented with 10% FCS (Invitrogen). Cells were co-transfected with plasmids encoding ICN1-Myc (plasmid pcDNA3-ICN1-Myc) or the indicated ICN1 point mutants together with HA-tagged FBW7 (Fig. 8e and Supplementary Fig. 6e ; cells were treated with proteasome inhibitor MG132 before collection).
MOLT-16 cells were cultured in RPMI 1640 with 10% FCS. Cells were transduced with lentiviruses encoding control shRNAs or shRNAs against cyclin C, FBW7, CDK8, CDK19 or CDK3, and selected with puromycin. Alternatively, cells were transduced with retroviruses encoding empty vector, or human cyclin C, CDK8, CDK19 or CDK3 cDNA (plasmids pcDNA3-CDK-HA) and selected with puromycin ( Supplementary Fig. 3f ).
MOLT-4 cells were transduced with MSCV-IRES-GFP, MSCV-ICN1-WT-IRES-GFP (encoding C-terminally Myc-tagged wild-type ICN1), or MSCV-ICN1-P2515R-IRES-GFP (encoding C-terminally Myc-tagged ICN1-P2515R). GFP low cells were sorted by FACS. Before analyses, protein lysates were prepared with RIPA buffer, and immunoblotted with anti-Notch1 (D1E11, Cell Signaling, 1:1,000), anti-GFP (Clones 7.1/13.1, Roche, 1:1,000) and anti-Myc (71D10, Cell Signaling, 1:1,000) antibodies, to ascertain that Myc-tagged ICN1 was expressed at approximately the same level as the endogenous ICN1.
Cell lines were from ATCC or DSMZ and were tested for mycoplasma.
Cell cycle analysis. Cells were labelled with 10 µM BrdU for 60 min, fixed in 80%
ethanol, stained using FITC-labelled anti-BrdU antibody (556028, BD, 1:5) and 10 µg ml −1 propidium iodide, and analysed on an LSR II flow cytometer (BD). For the cell cycle re-entry analyses shown in Fig. 3c , MEFs were kept in DMEM without serum for 48 h, and then stimulated with DMEM plus the indicated concentrations of serum (FCS).
Real-time RT-PCR analysis. RNA was extracted using the RNeasy Mini Kit (Qiagen), and the reverse transcription (RT) reaction was performed using the First Strand cDNA Synthesis Kit (GE Health Care). After mixing the resultant template with Notch1-or HPRT-specific primers and with SYBR green PCR master mix (Applied Biosystems), PCR was performed with the 7300 Real Time PCR System (Applied Biosystems). Oligonucleotide primer sequences were as follows: Notch1 primers: Notch1-F: 5 -TGAGACTGCCAAA GTGTTGC-3 ; Notch1-R: 5 -GTGGGAGACAGAGTGGGTGT-3 ; HPRT primers: HPRT-F: 5 -CCTCTGGTAGATTGTCGCTT-3 ; HPRT-R: 5 -GAGAGCT TCAGACTCGTCTA-3 .
In vivo polyubiquitylation detection. For analysis of polyubiquitylation of the endogenous ICN1 (Fig. 5j) , thymuses were collected from cyclin C F/F /Mx1-Cre and cyclin C / /Mx1-Cre − mice, and thymocytes were cultured with MG132 (10 µM) for 6 h. Protein extracts were prepared in lysis buffer containing 100 mM iodoacetamide. Polyubiquitylated proteins were captured from cell extracts (containing 3.5 mg of protein) with Halo-TUBE as described previously 63 . Captured proteins were resolved on SDS-PAGE along with whole-cell extract and immunoblotted with the indicated antibodies.
For the analyses shown in Supplementary Fig. 6g , 293 cells were infected with lentiviral shRNA against GFP or cyclin C, and selected with puromycin. Knockdown cell lines were transfected with pcDNA3-ICN1-Myc and His-Ub. Thirty-six hours after transfection, cells were treated with 25 µM MG132 for 6 h before protein extraction. Extracts were incubated with Ni-NTA matrices at room temperature for 3 h in the presence of 6 M guanidine-HCl, pH 8.0. Immobilized proteins were resolved by SDS-PAGE and immunoblotted with an anti-Myc antibody.
Expression and purification of recombinant GST-ICN1 protein from bacteria. GST-ICN1 was expressed in BL-21 (DE3) bacteria. Expression of recombinant proteins was induced with 0.1 mM IPTG for 6 h at 37 • C. Bacteria were lysed by sonication in PBS at pH 7.4 containing 1% N -lauroyl sarcosine, 1 mM EDTA, 10 mM dithiothreitol and protease inhibitors, and GST-ICN1 protein was purified on glutathione beads. GST-ICN1 was then eluted from the beads with 25 mM glutathione, 200 mM NaCl, 50 mM Tris at pH 8.8, dialysed in kinase buffer and concentrated before the kinase reaction.
Expression and purification of recombinant cyclin C-CDK kinases from Sf9 cells. Human CDK19 and CDK3 cDNAs (both from Addgene) and human cyclin C cDNA were cloned into the pTriEx-5 vector (from T. Roberts, Dana-Farber Cancer Institute) using the following primers: 5 -GGGGGTACCCGATTATGATTT CAAGGCGAAGCT-3 and 5 -GGGAAGCTTGTACCGGTGGGCCTGGTGA-3 (CDK19); 5 -GGGGGATCCGGATATGTTCCAGAAGGTAGAG-3 and 5 -GGG AAGCTTATGGCGGAATCGCTGCAGCA-3 (CDK3); 5 -GGGGGATCCGGCAG GGAACTTTTGGCAGAG-3 and 5 -GGGAAGCTTAGATTGGCTGTAGCTAGA GTTCT-3 (cyclin C).
Sf9 cells were maintained in BacVector Insect cell medium. CDK19, CDK3 and cyclin C in pTriEx vectors (0.5 µg each) were individually co-transfected with BacMagic DNA into Sf9 cells using the BacMagic Transfection Kit (Novagen). Medium containing recombinant baculovirus (∼1 × 10 7 pfu ml −1 ) was collected after 5 days. Supernatants were then used to infect/co-infect Sf9 cells for 48 h to generate His-tagged cyclin C, cyclin C-CDK19 and cyclin C-CDK3. I-PER Insect Cell Protein Extraction Reagent (Thermo Scientific) supplemented with protease inhibitors was used to lyse insect cells, and kinase complexes were purified using an anti-His antibody immobilized on Protein A/G Plus-Agarose beads (Santa Cruz).
Expression and purification of recombinant cyclin C-CDK kinases from HEK293 cells. Mammalian expression vectors encoding His-tagged human CDK19 (pTriEx-5) and cyclin C (pCMV Sport6), or HA-tagged human CDK3 (pcDNA3) and cyclin C, or only His-tagged CDK19, only HA-tagged CDK3 or only cyclin C, were co-transfected into HEK293 cells using Lipofectamine 2000 (Invitrogen). Cells were collected after 48 h, sonicated and lysed in kinase buffer without ATP added. Anti-His antibody immobilized on Protein A/G Plus-Agarose beads (Santa Cruz) was used to purify His-CDK19-cyclin C protein complexes or His-CDK19. Anti-HA antibody immobilized on Protein A/G Plus-Agarose beads was used to purify HA-CDK3-cyclin C protein complexes or HA-CDK3.
In vitro kinase reactions. For cyclin C-CDK8 kinase assays, 0.1 µg of cyclin C-CDK8 (Life Technologies, PV4402) and 1 µg of GST-ICN1 protein immobilized on glutathione-Sepharose beads were used. For cyclin C-CDK19 and C-CDK3 assays, cyclin C-CDK complexes were purified from Sf9 or HEK293 cells as described above and used together with 0.5 µg of GST-ICN1. Kinase assays were performed in a final volume of 30 µl of kinase buffer (50 mM HEPES at pH 7.5, 10 mM MgCl 2 , 1 mM dithiothreitol, 1 mM EGTA, 0.1 mM NaF) containing 10 µM ATP and 0.4 mCi [γ−
32 P]ATP. After a 30 min incubation at 30 • C, proteins were resolved on SDS-PAGE gels and analysed by autoradiography.
For mass spectrometric analyses ( Supplementary Fig. 5 ), cyclin C-CDK19 or C-CDK3 complexes, purified from Sf9 cells, were incubated with 0.1 µg of the peptide N-EHPFLTPSPESPDQWFPK-C (from NeoBioLab), corresponding to amino acids 2507-2521 of Notch1, in 30 µl of kinase reaction mixture for 30 min at 30 • C. Samples were then analysed by mass spectrometry.
In vitro and in vivo Fbw7-binding assays. Fbw7 in vitro binding to immobilized GST-fusion proteins was performed as described previously 62 . Where indicated, GST-ICN1 fusion proteins were incubated with recombinant cyclin C-CDK8 (Invitrogen) in the presence of 0.2 µM cold ATP for 1 h before binding assays.
For in vivo binding assays, HeLa cells were transfected with an empty vector (EV) or Myc-tagged wild-type ICN1 or various ICN1 mutants along with HA-tagged Fbw7. Twenty hours after transfection, cells were treated with 15 µM MG132 overnight before collection for immunoprecipitation. Protein extracts were subjected to immunoprecipitation with an anti-HA antibody. Immunocomplexes were resolved on SDS-PAGE and immunoblotted with the indicated antibodies.
Detection of Notch1 ICN1 phosphorylation sites in vitro and in vivo.
To map cyclin C-CDK8 phosphorylation sites on ICN1, in vitro kinase assays were performed as above. GST-ICN1 fusion protein-coupled beads were incubated with cyclin C-CDK8 recombinant complex (Invitrogen) in the presence of 0.2 mM cold ATP for 1 h. Beads were washed three times with 50 µl of 50 mM Tris (pH 8.2). Beads were then resuspended in 50 µl of 50 mM Tris (pH 8.2) and digested with 0.5 µg of ASP-N overnight at 37 • C. The samples were then acidified using 50 µl of 1% formic acid and desalted using Stage-tips.
To map ICN1 phosphorylation status in vivo, 293 cells were transfected with Myc-ICN1. Forty hours after transfection, cells were treated with 10 µM MG132 for 10 h before collecting cell lysates for anti-Myc-immunoprecipitation. Myc immunoprecipitated beads were washed and treated as in the in vitro experiment.
To gauge cyclin C-CDK8 phosphorylation of T-ALL patient-derived Notch1 mutants, the following peptides were synthesized (from NeoBioLab), corresponding to amino acids 2507-2521 of Notch1: wild-type: N-EHPFLTPSPESPDQWFPK-C; P2513A: N-EHPFLTASPESPDQWFPK-C (mutated residue bold and underlined); P2513L: N-EHPFLTLSPESPDQWFPK-C; P2513S: N-EHPFLTSSPES PDQWFPK-C; P2514F: N-EHPFLTPFPESPDQWFPK-C; P2515R: N-EHPF LTPSRESPDQWFPK-C.
One microgram of peptides was used for the in vitro kinase reactions as above.
In in vitro and in vivo Notch1 phosphorylation analyses, samples were resuspended in 10 µl of 1% formic acid; subsequently 2 µl was used for analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). For the synthesized Notch1 peptide experiments, samples were resuspended in 100 µl and 2 µl was used for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis.
For in vitro and in vivo Notch1 phosphorylation analyses, mass spectrometry was performed using an LTQ-Orbitrap Elite hybrid or Q-exactive mass spectrometer (Thermo Fisher, San Jose). The raw, mzXML and results files have been deposited to the ProteomeXchange with identifier PXD001237 with detailed mass spectrometry methods. An in-house suite of software was used for peptide identifications using the Sequest algorithm. Sequest searches were performed using the target decoy strategy and identifications were filtered using a 1% false discovery rate using a linear discriminant analysis. More detailed methods accompany the ProteomeXchange submission above.
CGH and gene expression array. Microarray-based comparative genomic hybridization (array CGH) was performed using Human Genome CGH 244A microarrays (Agilent Technologies) on T-ALL diagnostic specimens collected with informed consent and institutional board review approval from 47 children with T-ALL treated on clinical trials Children's Oncology Group P9404 or Dana-Farber Cancer Institute 00-01 (refs 64,65), as described 66 . Array CGH analysis of human T-ALL cell lines was performed using Human Genome CGH 44A microarrays (Agilent Technologies). Another set contained 103 cases of childhood T-ALL as described previously 67 . Gene expression microarrays were performed on 40 of the primary T-ALL patient samples analysed by array CGH (shown in Fig. 7a ), using Affymetrix U133 Plus 2.0 arrays, as described previously 65, 66 . Cyclin C expression is from probe set 201955_at; CDK19 expression is from probe set 212897_at.
For the analyses shown in Fig. 2d ,e Affymetrix gene expression microarray data were normalized using RMA (ref. 68) . The log of the normalized gene expression data was then plotted.
Sequencing of CCNC in T-ALL patients. The full coding sequence of cyclin C (CCNC, CCDS34502, NM_005190) was sequenced by PCR amplification and Sanger sequencing, using genomic DNA from all primary T-ALL patient samples analysed by array CGH that had sufficient DNA available (n = 43 of 47 in Fig. 7a) . Sequencing was performed at Genewiz. Another set contained 104 cases of childhood T-ALL as described previously 67 . The sequencing was done by Beckman Coulter Genomics.
Sequencing of NOTCH1 gene in T-ALL patients. Mutational screening of the LNR, HD-N, HD-C, TAD and PEST domains of NOTCH1 was performed by denaturing high-performance liquid chromatography and Sanger sequencing from diagnostic bone marrow samples from 73 patients with T-ALL (55 adult, 6 adolescent and 12 pediatric) as previously described 51, 69 . Patient characteristics have been reported previously 51, 69, 70 . Ethical approval for the trials and tissue collection for research was obtained from the Multi-Centre Research Ethics Committees and local research ethics committees as appropriate and informed consent was provided according to the Declaration of Helsinki.
Statistical analyses. The data were analysed using two-tailed t-tests, log-rank tests or Mann-Whitney tests, as indicated. The data had a normal distribution and the variance was similar between the groups being statistically compared. All western blotting or histological analyses have been repeated at least 3 times.
Accession numbers. Array CGH data are available on the NCBI Gene Expression Omnibus (GEO) website under accession numbers GSE14959 and GSE7615, gene expression data in T-ALL under accession number GSE14618, and microarray data of cyclin C-null cells under accession number GSE58712. Mass spectrometry raw, mzXML and results files have been deposited to the ProteomeXchange with the identifier PXD001237 along with detailed methods.
